41270-96-6

基本信息
4-碘-6-苯基嘧啶
MIF Antagonist III, 4-IPP
4-IODO-6-PHENYLPYRIMIDINE
Pyrimidine, 4-iodo-6-phenyl-
4-IPP (4-Iodo-6-phenylpyrimidine)
MIF Antagonist III, 4-IPP - CAS 41270-96-6 - Calbiochem
物理化学性质
沸点 | 380.2±30.0 °C(Predicted) |
密度 | 1.728±0.06 g/cm3(Predicted) |
储存条件 | -20°C |
溶解度 | 在DMSO中的溶解度为10mg/mL(透明溶液,加热) |
酸度系数(pKa) | -0.54±0.17(Predicted) |
形态 | 粉末 |
颜色 | 白色至米色 |
InChIKey | ZTCJXHNJVLUUMR-UHFFFAOYSA-N |
安全数据
危险性符号(GHS) | ![]() ![]() GHS05,GHS07 |
警示词 | 危险 |
危险性描述 | H302-H315-H318-H335 |
防范说明 | P261-P280-P305+P351+P338 |
危险品标志 | Xn |
危险类别码 | 22-37/38-41 |
安全说明 | 26-39 |
WGK Germany | 3 |
4-IODO-6-PHENYLPYRIMIDINE价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-110063 | 4-IPP | 41270-96-6 | 1 mg | 400元 |
2025/02/08 | HY-110063 | 4-IODO-6-PHENYLPYRIMIDINE 4-IPP | 41270-96-6 | 5mg | 1150元 |
2025/02/08 | HY-110063 | 4-IODO-6-PHENYLPYRIMIDINE 4-IPP | 41270-96-6 | 10mM * 1mLin DMSO | 1241元 |
常见问题列表
Target | Value |
MIF
() |
4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity.
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes.
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation.
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner.
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption .
Cell Cytotoxicity Assay
Cell Line: | BMMs |
Concentration: | 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM |
Incubation Time: | 24 hours, 72 hours |
Result: | Inhibited osteoclastogenesis in a dose-dependent manner. |
Western Blot Analysis
Cell Line: | BMMs |
Concentration: | 5 μM,10 μM, 20 μM |
Incubation Time: | 1 day, 3 days, 5 days |
Result: | Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation.
Animal Model: | 8-weeks-old C57BL/6J male mice |
Dosage: | 1 mg/kg, 5 mg/kg |
Administration: | Intraperitoneal injection; every 2 days; for 8 weeks |
Result: | Alleviated OVX-induced osteoporosis. |